In a small study with a mouse model of sporadic amyotrophic lateral sclerosis (sALS), perampanel administration successfully prevented the progressive loss of motor neurons caused by the conditional knockout of Adar2 and the subsequent excitotoxicity due to Gria2 under-editing.24 The clinical trials of perampanel efficacy in treatment of patients with sALS are ongoing.25 This drug is currently approved for the treatment of intractable epilepsy and could allow a better seizure control in ADARB1 patients. Here, ADARB1 is linked to sporadic amyotrophic lateral sclerosis.